Associations of serum fetuin-A levels with insulin resistance and vascular complications in patients with type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 10, Issue 5, 2013, Pages 459-467

  Jung, Chan Hee ^a   Kim, Bo Yeon ^a   Kim, Chul Hee ^a   Kang, Sung Koo ^a   Jung, Sang Hee ^b   Mok, Ji Oh ^a  

^a Soonchunhyang University   (South Korea)

^b CHA University   (South Korea)

Author keywords

Fetuin A; insulin resistance; metabolic syndrome; microangiopathies; type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; C PEPTIDE; CHOLESTEROL; FETUIN A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; AUTONOMIC NEUROPATHY; CHOLESTEROL BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PROTEIN BLOOD LEVEL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

FETUIN-A; INSULIN RESISTANCE; METABOLIC SYNDROME; MICROANGIOPATHIES; TYPE 2 DIABETES MELLITUS;

ADIPONECTIN; ADULT; AGED; ALPHA-2-HS-GLYCOPROTEIN; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84882368793     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113490766     Document Type: Article

References (33)

1. Giacco F, Brownless M. Oxidative stress and diabetic complications. Circ Res. 2010 ; 107: 1058-1070
2. Denecke B, Graber S, Schafer C, et al. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003 ; 376: 135-145
3. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glyco-protein/fetuin-A is a systematically acting inhibitor of ectopic calcification. J Clin Invest. 2003 ; 112: 357-366
4. Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993 ; 7: 1445-1455
5. Song A, Xu M, Bi Y, et al. Serum fetuin-A associates with type 2 diabetes and insulin resistance in Chinese adults. PLoS One. 2011 ; 6: e19228
6. Mori K, Emoto M, Yokoyama H, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care. 2006 ; 29: 462-468
7. Ix JH, Wassel CL, Kanaya AM, et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA. 2008 ; 300: 182-188
8. Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008 ; 118: 2555-2562
9. Hermans MM, Brandenburg V, Ketteler M, et al. Netherlands cooperative study on the adequacy of dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007 ; 72: 202-207
10. Kettler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003 ; 361: 827-833
11. Lorant DP, Hoellerl F, Grujicic M, et al. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011 ; 34: 156-161
12. Eraso LH, Ginwala N, Qasim AN, et al. Association of lower plasma fetuin-A levels with peripheral arterial disease in type 2 diabetes. Diabetes Care. 2010 ; 33: 408-410
13. Roos M, Oikonomou D, von Eynatten M, et al. Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol. 2010 ; 9: 48
14. Ewing DJ, Martyn CN, Young RJ, et al. The value of cardiovascular autonomic function test: 10 years experience in diabetes. Diabetes Care. 1985 ; 8: 491-498
15. Bellavere F, Bosello G, Fedele D, et al. Diagnosis and management of diabetic autonomic neuropathy. Br Med J (Clin Res Ed). 1983 ; 287: 61
16. O'Brien IAD, O'Hare JP, Lewin IG, et al. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. Q J Med. 1986 ; 61: 957-967
17. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497
18. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008 ; 57: 2762-2767
19. Ishibashi A, Ikeda Y, Ohguro T, et al. Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb. 2010 ; 17: 925-933
20. Ix JH, Biggs ML, Mukamal KJ, et al. Association of fetuin-A with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation. 2012 ; 125: 2316-2322
21. Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008 ; 3: e1765
22. Xu Y, Xu M, Bi Y, et al. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis. 2011 ; 216: 180-186
23. Roos M, von Eynatten M, Heemann U, et al. Serum fetuin-A, cardiovascular risk factors and 6-year follow-up outcome in patients with coronary heart disease. Am J Cardiol. 2010 ; 105: 1666-1672
24. Kim TH, Kim DJ, Lim S, et al. Prevalence of the metabolic syndrome in type 2 diabetic patients. Korean Diabetes J. 2009 ; 33: 40-47
25. Ramadan A, Shoukry A, Ismail MI, et al. Serum fetuin-A levels in type 2 diabetes patients with early diabetic nephropathy: it's relation to diabetes control. J Am Sci. 2011 ; 7: 759-765
26. Ix JH, Shlipak MG, Brandenburg VM, et al. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006 ; 113: 1760-1767
27. Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant. 2006 ; 21: 1293-1299
28. Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant. 2008 ; 23: 3263-3271
29. Roos M, Richart T, Kouznetsova T, et al. Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept. 2009 ; 154: 39-43
30. Ix JH, Barrett-Connor E, Wassel CL, et al. The associations of fetuin-A with subclinical cardiovascular disease in community-dwelling persons: The Rancho Bernardo Study. J Am Coll Cardiol. 2011 ; 5: 2372-2379
31. Methrotra R, Westenfeild R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005 ; 67: 1070-1077
32. Mori K, Emoto M, Araki T, et al. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism. 2008 ; 57: 1248-1252
33. Muniyappa R, Lee SH, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008 ; 294: E15 - E26